Daptomycin: A novel agent for Gram-positive infections

Expert Opinion on Investigational Drugs

Volumn 8, Issue 8, 1999, Pages 1223-1238

  Tally, F P ^a   Zeckel, M ^a   Wasilewski, M M ^a   Carini, C ^a   Berman, C L ^a   Drusano, G L ^a   Oleson, F B ^a  

^a CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Antibiotics; Bacteremia; Coagulase negative staphylococci; Daptomycin; Endocarditis; Glycopeptide intermediately susceptible Staphylococcus aureus; Gram positive bacteria; Methicillin resistant Staphylococcus aureus; Penicillin resistant Streptococcus pneumoniae; Resistance; Skin infection; Soft tissue infection; Vancomycin resistant enterococci

Indexed keywords

CREATINE KINASE; DAPTOMYCIN;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COAGULASE POSITIVE STAPHYLOCOCCUS; CREATINE KINASE BLOOD LEVEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ENDOCARDITIS; ENTEROCOCCUS; GASTROINTESTINAL SYMPTOM; GRAM POSITIVE BACTERIUM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE DISEASE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; REVIEW; SKIN INFECTION; SKIN IRRITATION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE;

EID: 0032846315     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.8.8.1223     Document Type: Review

References (82)

1. Eliopoulos GM, Willey S, Reiszner E, Spitzer PG, Caputo G, Moellering RC: In vitro and in vivo activity of LY 146032, a new cyclic lipopeptide antibi-otic. Antimicrob. Agents Chemother. (1986) 30:532–535.
2. Fass RJ, Helsel VL: In vitro activity of LY146032 against staphylococci, streptococci, and enterococci. Antimi-crab. Agents Chemother. (1986) 30:781–784.
3. Jones RN, Barry AL: Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations. Antimicrob. Agents Chemother. (1987) 31:625–629.
4. Silva M, Jacobus NV, Gorbach SL: In vitro activity of LY146032 against gram-positive bacteria. Diagn. Microbial. Infect. Dis. (1988) 9:79–85.
5. Li T, Zhang X, Oliver N, Andrew T, Silverman J, Tally FP: In vivo efficacy of daptomycin against systemic infection induced by vancomycin-resistant Enterococcus faecalis (VRE) in the mouse. Program and Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (1998). Abstract F–116.
6. Daptomycin's efficacy in an animal model of VRE-induced bacteremia.
7. Jacobus NV, Mcdermott L, Lonks JR, Boyce JM, Snydman DR: In vitro activity of daptomycin against resistant gram-positive pathogens. Program and Abstracts of the 38th Intel-science Conference on Antimicro-bial Agents and Chemotherapy San Diego, CA, USA (1998). Abstract F–112.
8. Daptomycin's in vitro activity against resistant Gram-positive pathogens.
9. Canepari P, Boaretti M, DEL MAR LLE0 M, SATTA G:Lipoteichoic acid as a new target for activity of antibi-otics: Mode of action of daptomycin (LY146032). Antimicrob. Agents Chemother. (1990) 34:1220–1226.
10. Boaretti M, Canepari P, DEL MAR LLE0 M, SATTA G:The activity of daptomycin on Enterococcus faecium protoplasts: Indirect evidence supporting a novel mode of action on lipoteichoic acid synthesis. J. Antimicrob. Chemother. (1993) 31:227–235.
11. Boaretti M, Canepari P: Identification ofdaptomycin-binding proteins in the membrane of Enterococcus hirae. Antimicrob. Agents Chemother. (1995) 39:2068–2072.
12. Alborn WE, JR, Allen NE, Preston DA: Daptomycindisrupts membrane potential in growing Staphylo-coccus aureus. Antimicrob. Agents Chemother. (1991) 35:2282–2287.
13. Allen NE, Alborn WE, Jr, Hobbs JN, Jr.: Identificationof membrane potential-dependent amino acid transport by daptomycin. Antimicrob. Agents Chemother. (1991) 35:2639–2642.
14. Rybak MJ, Hershberger E, Moldovan T: Compara-tive in vitro activity of daptomycin vs. vancomycin, linezolid and Synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susceptible (VS) and resistant enterococci (VRE). Program and Abstracts of the 38th Intel-science Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (1998). Abstract C–146.
15. Daptomycin's in vitro activity against resistant Gram-positive pathogens.
16. Tenover FC: Personal communication. NosocomialPathogens Laboratory, Centers for Disease Control and Prevention, Atlanta, GA, USA (February 1998).
17. DATA ON FILE: Clinical Microbiology Institute, Wilsonville,OR, USA.
18. DATA ON FILE: Alden Research Laboratory, Holden, MA,USA.
19. Hanberger H, Nilsson LE, Mailer R, Isaksson B: Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postanti-biotic effect and influence of Ca2+ and albumin on these drugs. Antimicrob. Agents Chemother. (1991) 35:1710–1716.
20. Daptomycin's rapid bactericidal activity in comparison tovancomycin.
21. Vance-Bryan K, Larson TA, Rotschafer JC, Toscano JP: Investigation of the early killing of Staphylococcus aureus by daptomycin by using an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. (1992) 36:2334–2337.
22. Lamp KC, Rybak MJ, Bailey EM, Kaatz GW: In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin. Antimicrob. Agents Chemother. (1992) 36:2709–2714.
23. Benson CA, Beaudette F, Trenholm G: Comparative in-vitro activity of LY146032 a new peptolide, with vancomycin and eight other agents against Gram-positive organisms. J. Antimicrob. Chemother. (1987) 20:191–196.
24. Blenkharn JI, Darrell JH: Comparative in vitro activity of daptomycin (LY146032) and vancomycin against gram-positive cocci determined using a pharmacokinetic model. Eur. J. Clin. Microbic. Infect. Dis. (1989) 8:734–737.
25. El-Mady A, Mortensen JE: The bactericidal activity of ampicillin, daptomycin, and vancomycin against ampicillin-resistant E. faecium. Diagn. Microbiol. Infect. Dis. (1991) 14:141–145.
26. Fontana R, Grossato A, Ligozzi M, Tonin EA: Invitro response to bactericidal activity of cell wall-active antibiotics does not support the general opinion that enterococci are naturally tolerant to these antibiotics. Antimicrob. Agents Chemother. (1990) 34:1518–1522.
27. Louie A, Baltch AL, Ritz WJ, Smith RP, Asperilla M:Comparison of in vitro inhibitory and bactericidal activities of daptomycin (LY 146032) and four reference antibiotics, singly and in combination, against gentamicin-susceptible and high-level-gentamicin-resistant enterococci. Chemotherapy (1993) 39:302–310.
28. Mobarakai N, Quale JM, Landman D: Bactericidalactivities of peptide antibiotics against multidrug-resistant Enterococcus faecium. Antimicrob. Agents Chemother. (1994) 38:385–387.
29. Stratton CW, Liu C, Ratner HB, Weeks LS: Bacteri-cidal activity of deptomycin (LY146032) compared with those of ciprofloxacin, vancomycin, and ampicillin against enterococci as determined by kill-kinetic studies. Antimicrob. Agents Chemother. (1987) 31:1014–1016.
30. Van Der Auwera P: Ex vivo study of serum bacteri-cidal titers and killing rates of daptomycin (LY146032) combined or not combined with amikacin compared with those of vancomycin. Antimicrob. Agents Chemother. (1989) 33:1783–1790.
31. Bush LM, Boscia JA, Wendeler M, Pitsakis PG, Kaye D: In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains. Antimicrob. Agents Chemother. (1989) 33:1198–1200.
32. Hanberger H: Pharmacodynamic effects of antibi-otics. Studies on bacterial morphology, initial killing, postantibiotic effect and effective regrowth time. Scand.J. Infect. Dis. (1992) Suppl. 81:1–52.
33. Tripodi M-F, Adinolfi LE, Utili R, Marrone A, RUGGIERO G: Influence of subinhibitory concentra-tions of loracarbef (LY 163892) and daptomycin (LY 146032) on bacterial phagocytosis, killing and serum sensitivity. J. Antimicrob. Chemother. (1990) 26:491–501.
34. Oliver N, Andrew T, Silverman JA, Li T: In vitro studies on resistance to the lipopeptide antibiotic daptomycin. Program and Abstracts of the 38th InterscE ence Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA (1998). Abstract F–117.
35. Daptomycin exhibits a very low rate of resistance in vitro.
36. Kaatz GW, Seo SM, Lundstrom TS: Development of daptomycin resistance (Di) in experimental Staphylo-coccus aureus (SA) endocarditis. Program and Abstracts of the 33rd Intel-science Conference on Antimicrobial Agents and Chemotherapy (1993). Abstract 155.
37. DATA ON FILE: Adams, and Van Rosenstiel, Eli Lilly and Company, IND No. 27,627: 13,337.
38. DATA ON FILE: IND No. 57,693, Table 10.21, Cubist Pharmaceuticals, Inc.
39. Smith K, Cobbs G, Dill R, Lyon D, Graves A, Avent K: Daptomycin versus vancomycin treatment for Staphylococcus aureus bacteremia in a murine model. Chemotherapy (1990) 36:428–434.
40. DATA ON FILE: In vivo models. Cubist Pharmaceuticals, Inc., IND No. 57,693.
41. Nord CE, Lindmark A, Persson I: LY146032 treatment of Clostridium difficile colitis in hamsters. Eur. J. Clin. Microbiol. Infect. Dis. (1987) 6:686.
42. Bush LM, Boscia JA, Kaye D: Daptomycin (LY146032) treatment of experimental enterococcal endocarditis. Antimicrob. Agents Chemother. (1988) 32:877–881.
43. Daptomycin effectiveness in an animal model ofendocarditis.
44. Cantoni L, Glauser MP, Bille J: Comparative efficacy of daptomycin, vancomycin and cloxacillin for the treatment of Staphylococcus aureus endocarditis in rats and role of test conditions in this determination. Antimicrob. Agents Chemother. (1990) 34:2348–2353.
45. Daptomycin efficacy against S. aureus-induced endocar-ditis in rats.
46. Caron F, Kitzis M-D, Gutmann L et al Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob. Agents Chemother. (1992) 36:2611–2616.
47. Daptomycin effectiveness against VRE-induced experi-mental endocarditis.
48. Hindes RG, Willey SH, ELIOPOULOS GM et al: Treatment of experimental endocarditis caused by I3-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrob. Agents Chemother. (1989) 33:1019–1022.
49. Kaatz GW, Seo SM, Reddy VN, Bailey EM, Rybak MJ: Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylo-coccus aureus endocarditis. Antimicrob. Agents Chemother. (1990) 34:2081–2085.
50. Kennedy S, Chambers HF: Daptomycin (LY146032) for prevention and treatment of experimental aortic valve endocarditis in rabbits. Antimicrob. Agents Chemother. (1989) 33:1522–1525.
51. Leggett J, Totsuka K, Ebert S, Vogelman B, Craigwa: Pharmacodynamic and pharmacokinetic parame-ters (PKPs) affecting activity of LY 146032 against Staphylococcus aureus. Program and Abstracts of the 27th Intel-science Conference on Antimicrobial Agents and Chemotherapy. New York, USA (1987).
52. Daptomycin's Cm, or AUC-driven efficacy in an animal model of thigh infection.
53. Miniter PM, Patterson TF, Johnson MA, Andriole VT: Activity of LY146032 in vitro and in experimental enterococcal pyelonephritis. Antimicrob. Agents Chemother. (1987) 31:1199–1203.
54. Sapico FL, Ginunas VJ, Canawati HN, Montgomerie JZ: LY146032, alone and in combina-tion with gentamicin, for the treatment of entero-coccal pyelonephritis in the rat model. Antimicrob. Agents Chemother. (1988) 32:81–83.
55. Mader JT, Adams K: Comparative evaluation of daptomycin (LY146032) and vancomycin in the treatment of experimental methicillin-resistant Staphylococcus aureus osteomyelitis in rabbits. Antimicrob. Agents Chemother. (1989) 33:689–692.
56. Luu QN, Buxton TB, Nelson DR, Rissing JP: Treatment of chronic experimental Staphylococcus aureus osteomyelitis with LY146032 and vancomycin. Eur. j Clin. Microbiol. Infect. Dis. (1989) 8:562–563.
57. Dong M-Y, Chang T-W, Gorbach SL: Treatment ofClostridium difficile colitis in hamsters with a lipopeptide antibiotic, LY146032. Antimicrob. Agents Chemother. (1987) 31:1135–1136.
58. Kephart PA, Esposito AL: Comparison of the investi-gational drug, LY146032, with vancomycin in experi-mental pneumonia due to methicillin-resistant Staphylococcus aureus. J. Antimicrob. Chemother. (1988) 21:33–39.
59. Verghese A, Haire C, Franzus B, Smith K: LY146032in a hamster model of Staphylococcus aureus pneumonia-effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy (1988) 34:497–503.
60. Ramos MC, Grayson ML, Eliopoulos GM, Bayer AS: Comparison of daptomycin, vancomycin, and ampicillin-gentamicin for treatment of experimental endocarditis caused by penicillin-resistant entero-cocci. Antimicrob. Agents Chemother. (1992) 36:1864–1869.
61. Oleson FB, JR, Berman CL, Kirkpatrick JB, Regan KS, Lai J-J, Tally FP: Once-daily dosing decreases toxicity of daptomycin. Toxicol. ScL (1999) 48:322.
62. Daptomycin's myotoxicity is dependent on dosing frequency.
63. Lee BL, Sachdeva M, Chambers HF: Effect of protein binding of daptomycin on MIC and antibacterial activity. Antimicrob. Agents Chemother. (1991) 35:2505–2508.
64. Woodworth JR, Nyhart EH, Brier GL, Wolny JD, Black HR: Single-dose pharmacokinetics and antibac-terial activity of daptomycin, a new lipopeptide antibi-otic, in healthy volunteers. Antimicrob. Agents Chemother. (1992) 36:318–325.
65. Clinical pharmacokinetic profile of daptomycin at singledoses up to 6 mg/kg.
66. DATA ON FILE: Study B8B-LC-AVAC. Cubist Pharmaceuti-cals, Inc.
67. DATA ON FILE: Study B8B-LC-AVAJ. Cubist Pharmaceuti- cals, Inc.
68. DATA ON FILE: Study B8B-EW-0001. Cubist Pharmaceuti-cals, Inc.
69. Rowland M, Tozer TN: In: Clinical Pharmacokinetics: Concepts and Applications (3rd edition) Williams & Wilkins, Baltimore, MD, USA (1995):272–273.
70. DATA ON FILE: Study B8B-MC-AVAE. Cubist Pharmaceuti-cals, Inc.
71. DATA ON FILE: Study B8B-MC-AVAM. Cubist Pharmaceu-ticals, Inc.
72. DATA ON FILE: Study B8B-MC-AVAG. Cubist Pharmaceuti-cals, Inc.
73. Woodworth JR, Nyhart EH, Wolny JD, Brier GL, Black HR: Tobramycin and daptomycin disposition when co-administered to healthy volunteers. J. Antimi-crob. Chemother. (1994) 33:655–659.
74. Couture M, Simard M, Gourde P et al.: Daptomycin may attenuate experimental tobramycin nephrotox-icity by electrostatic complexation to tobramycin. Antimicrob. Agents Chemother. (1994) 38:742–749.
75. Kreft B, De Wit C, Krech R, Marre R, Schulze E, Sack K: Experimental studies on nephrotoxicity and pharmacokinetics of LY 146032 (daptomycin) in rats. J. Antimicrob. Chemother. (1990) 25:635–643.
76. ThibaulT N, Grenier L, Simard M, Bergeron MG, Beauchamp D: Protection against gentamicin nephro-toxicity by daptomycin in nephrectomized rats. Life ScL (1995) 56:1877–1887.
77. Thibault N, Grenier L, Simard M, Bergeron MG, Beauchamp D: Attenuation by daptomycin of gentamicin-induced experimental nephrotoxicity. Antimicrob. Agents Chemother. (1994) 38:1027–1035.
78. Beauchamp D, Pellerin M, Gourde P, Pettigrew M, Bergeron MG: Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob. Agents Chemother. (1990) 34:139–147.
79. Wood CA, Finkbeiner HC, Kohlhepp SJ, Kohnen PW, Gilbert DN: Influence of daptomycin on staphy-lococcal abscesses and experimental tobramycin nephrotoxicity. Antimicrob. Agents Chemother. (1989) 33:1280–1285.
80. DATA ON FILE: Study B8B-MC-AVAP. Cubist Pharmaceuti-cals, Inc.
81. DATA ON FILE: LI TC et al, Cubist Pharmaceuticals, Inc.
82. DATA ON FILE: IND No. 57,693, Table 8.7, Cubist Pharma-ceuticals, Inc.